Mirador Therapeutics Licenses KP-301, a Long-Acting Anti-C5a Antibody, Expanding into ANCA-Associated Vasculitis
核心洞察
Mirador Therapeutics (搜索) secured exclusive worldwide rights to KP-301 from Kira Pharmaceuticals (搜索), a long-acting anti-C5a (搜索) antibody targeting C5a/C5aR (搜索)-mediated inflammation.
The company plans to initiate a Phase 1 study by year-end 2026 and a Phase 2 trial in ANCA-associated vasculitis (搜索) (AAV) in the first half of 2027.
KP-301 employs a pH-dependent "sweeping" mechanism designed to enable sustained C5a (搜索) inhibition with infrequent, low dosing suited for chronic treatment.
Mirador Therapeutics (搜索), a clinical-stage precision medicine company based in San Diego, announced today that it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals (搜索) for KP-301, a potentially long-acting, sweeping anti-C5a (搜索) antibody. The agreement expands Mirador's precision immunology portfolio into inflammatory vascular disease, with an initial focus on ANCA-associated vasculitis (搜索) (AAV), a serious autoimmune condition characterized by inflammation and destruction of small blood vessels.
Under the terms of the deal, Mirador receives exclusive worldwide rights to develop, manufacture, and commercialize KP-301 across all indications. Kira will receive $12 million upon signing and is eligible to receive development and sales milestone payments.
Targeting the C5a (搜索)/C5aR (搜索) Axis in AAV
The C5a (搜索)/C5aR (搜索) axis is clinically and commercially validated in AAV. While C5aR inhibition has demonstrated meaningful clinical benefit and commercial adoption in this indication, Mirador believes there remains a need for effective next-generation therapies with a favorable safety and tolerability profile.
"Our strategy is disciplined: We take on big problems in I&I and pair each program with the modality most likely to succeed for patients. KP-301 is a textbook example of that thesis," said Mark C. McKenna, Chairman and CEO of Mirador. "The biology of complement-driven vascular inflammation is well established, yet significant unmet need remains. KP-301 gives us the opportunity to deliver the benefit of C5a (搜索) signaling inhibition through a differentiated, long-acting antibody, and it expands our portfolio into inflammatory vascular disease, where the science, the modality and the unmet need clearly align."
A Differentiated "Sweeping" Antibody Design
KP-301 is engineered as a long-acting, potent, and selective C5a (搜索) blocker that incorporates next-generation pH-dependent target binding and antibody recycling. This design is intended to overcome target burden that would otherwise limit the dosing interval. The "sweeping" mechanism enables sustained C5a signaling inhibition at low, infrequent dosing suited to chronic treatment, potentially offering durable target coverage and infrequent administration in chronic complement-mediated disease.
Clinical Development Timeline
Mirador intends to initiate a Phase 1 study of KP-301 by year-end 2026, followed by a Phase 2 AAV study in the first half of 2027. The company also plans to pursue monotherapy and combination expansion into additional inflammatory disease indications.
The addition of KP-301 reflects Mirador's Mirador360 precision development engine, which leverages more than 2.5 million molecular profiles across immune-mediated diseases to support target validation, patient stratification, and indication prioritization. Mirador, which has raised over $650 million from leading life sciences investors, anticipates multiple clinical readouts by year-end 2027.